With 1 mL bacteriostatic water
4.0 units
Page last checked
Reconstitution · IGF-1 LR3
Pick the vial, the water you added and the dose. Get the exact draw in units for the syringe in your hand.
Step 1 of 4
This vial holds 1,000 mcg in total.
U-100 insulin syringe · 1 mL · lines every 2 units · 1 unit = 0.01 mL
8.0 units on a U-100 insulin syringe · 1 mL · lines every 2 units, which is 0.08 milliliters. The draw lands on a syringe line.
Your address is used to send this one card. The email also includes an optional link for updates when our data changes. Nothing else is sent unless you choose that link, and you can unsubscribe anytime.
IGF-1 LR3 is a re-engineered insulin-like growth factor 1. The changes stop your carrier proteins holding it back, so it stays active far longer than the natural version. Bodybuilding forums use it to grow muscle, usually on the back of a growth-hormone course.
Its documented job is industrial. It is sold as a catalogue reagent for growing cells in tanks, where staying active is exactly the selling point. No study of it in people has ever been registered. The change that makes it useful in a tank is the change that removes your body’s own brake on the signal.
No completed controlled human trial has shown which dose works for IGF-1 LR3. The range people report using is not a study result, tested schedule or recommendation.
no human dose shown to work
Each row uses 1 mg and the liquid volume shown. Dividing the amount by that volume gives the calculated concentration. The rows are arithmetic examples, not alternative product preparations.
With 1 mL bacteriostatic water
4.0 units
With 2 mL bacteriostatic water
8.0 units
| Bacteriostatic water | Concentration | Per U-100 unit | Draw for 40 mcg | Nearest syringe line |
|---|---|---|---|---|
| 1 mL | 1.00 mg/mL | 10.0 mcg | 4.0 u · 0.040 mL | exactly 4 u |
| 2 mL | 0.50 mg/mL | 5.0 mcg | 8.0 u · 0.080 mL | exactly 8 u |
The amount, liquid volume and dose shown here are the calculator’s starting example for IGF-1 LR3. Replace them with your own values. Every result in the table is calculated from those inputs.
The larger IGF-1 LR3 vial preset contains ten times the amount in the smaller one. With the same water volume, that means ten times the concentration. Selecting the wrong vial changes the result far more than rounding does.
The vial field uses the amount of IGF-1 LR3, not the physical size of the glass container. A container’s appearance does not establish the mass or concentration needed for the calculation.
For the same entered dose and water volume, the larger vial preset produces a smaller draw. The smaller preset produces a larger draw. The tenfold difference comes from the amount in the vial and remains part of the calculation even when the containers look similar.
Increasing the water volume lowers the calculated concentration. The same entered dose then occupies more space on the syringe. The result’s measurement details show whether that volume fits the selected syringe and how it relates to its markings.
This change does not add IGF-1 LR3 to the vial. At the same dose, the calculated number of doses stays the same. A larger draw therefore does not mean a larger supply, and a dose count does not establish how long a preparation can be stored.
The tool uses the substance name and mass entered. It cannot test whether a vial contains IGF-1 LR3, confirm its purity or assess whether it is suitable for a person.
A result that is easy to read on a syringe remains an arithmetic result. The compound guide carries the separate evidence discussion; the calculator does not turn a laboratory-use description into a human dosing instruction.
The reported IGF-1 LR3 range comes from a review of how people use it, not a human dose trial of this analogue. Despite the similar name, it is not mecasermin, the approved medicine made with human IGF-I.
Mecasermin’s label applies to that drug and the patients it treats. It cannot supply a starting dose or schedule for this analogue. Nor can its side-effect rates tell us how often the same events would occur with IGF-1 LR3.
The calculation assumes the entered vial strength is correct. Too much or too little ingredient changes the actual amount in each draw. That uncertainty is not merely a question of wasting powder or money.
The review describes repeated use and breaks as reports of practice. A supply estimate can count doses under a schedule you enter. It does not show that the cycle works or that a mixed vial will keep for that long.
Mecasermin’s label applies to that drug and the patients it treats. It cannot supply a starting dose or schedule for this analogue. Nor can its side-effect rates tell us how often the same events would occur with IGF-1 LR3.
The calculation assumes the entered vial strength is correct. Too much or too little ingredient changes the actual amount in each draw. That uncertainty is not merely a question of wasting powder or money.
The review describes repeated use and breaks as reports of practice. A supply estimate can count doses under a schedule you enter. It does not show that the cycle works or that a mixed vial will keep for that long.
Mix 1 mg into 2 mL and one U-100 unit carries 5.0 mcg. The table shows how much peptide is in each numbered syringe line. These are conversion examples, not suggested doses.
| U-100 line | Volume | Mass (mcg) | Mass (mg) |
|---|---|---|---|
| 10 u | 0.10 mL | 50 mcg | 0.05 mg |
| 20 u | 0.20 mL | 100 mcg | 0.1 mg |
| 30 u | 0.30 mL | 150 mcg | 0.15 mg |
| 40 u | 0.40 mL | 200 mcg | 0.2 mg |
| 50 u | 0.50 mL | 250 mcg | 0.25 mg |
| 60 u | 0.60 mL | 300 mcg | 0.3 mg |
| 70 u | 0.70 mL | 350 mcg | 0.35 mg |
| 80 u | 0.80 mL | 400 mcg | 0.4 mg |
| 90 u | 0.90 mL | 450 mcg | 0.45 mg |
| 100 u | 1.00 mL | 500 mcg | 0.5 mg |
The math is only one part of the question. These guides cover the compound, published doses, side effects, mixing steps and supplies.